Merck KGaA Stock Timeline

2026 (June–Sept) — Strategic acquisitions and strong Q2 results

Merck announced and completed several acquisitions, including a definitive agreement to acquire Terns Pharmaceuticals, while reporting strong Q2 2026 results and raising full-year guidance. The narrative shifted toward an innovation-and-launch-driven growth story as recent approvals and M&A strengthened the oncology and infectious-disease pipeline. Investor discussion centered on durable top-line growth from new products and the company's evolution from legacy pharmaceuticals and chemicals toward higher-growth life-sciences and biopharma. Q2 2026 worldwide sales reached $16.6 billion, with full-year 2026 sales anticipated between $66.3–$67.3 billion [8]. Merck entered a definitive agreement to acquire Terns Pharmaceuticals in March 2026 [5][12].

2025 (full year) — Solid organic growth, stable dividend policy

Merck delivered full-year 2025 results with organic net-sales growth and higher EBITDA pre. The Executive and Supervisory Boards proposed an unchanged dividend for the 2025/2026 cycle. Investors viewed the company as delivering profitable growth with disciplined cost control and increasing cash returns to shareholders, reinforcing a dividend-and-growth compounder narrative while awaiting payoff from pipeline launches and business development activity. Group net sales for the 2024/2025 reporting cycle stood at approximately €21.2 billion (2024 reported), with full-year 2025 net sales guidance of €21.5–€22.9 billion and EBITDA pre guidance of €6.1–€6.6 billion [4][3]. The Executive and Supervisory Boards proposed an unchanged dividend of €2.20 per share for the 2025 fiscal year [7].

2024 (full year) — Portfolio transformation, margin expansion

Full-year 2024 results showed organic sales growth, higher EBITDA pre, and improved operating cash flow. Management highlighted portfolio transformation and contributions from launches in Healthcare and Animal Health. Market perception improved as the company demonstrated margin expansion and cash generation while R&D phasing and selective investments signaled disciplined reinvestment. Investors increasingly framed Merck as executing a multi-year transformation toward higher-growth, higher-margin businesses. Full-year net sales increased to €21.2 billion (organic +2.0%), EBITDA pre rose to €6.1 billion (organic +6.9%), EBITDA pre margin reached 28.7%, operating cash flow grew to €4.6 billion, EPS pre was €8.63, and the dividend proposal was €2.20 per share for 2024 [4].

2023 — Continued cash returns and stable financial policy amid pipeline work

Merck continued steady dividend increases and share repurchase activity alongside ongoing clinical and regulatory progress in key development programs. Public filings and presentations emphasized payout ratio targets and capital allocation discipline. Investors saw the company as a reliable cash returner with a balanced capital allocation approach (dividends and buybacks) while awaiting material clinical readouts and regulatory milestones that could alter growth trajectory. The stock retained attributes of a dividend compounder with upside optionality from pipeline successes. The company maintained dividend increases and stability within a target payout ratio band (approximately 20–25% of EPS pre) and continued returning capital via dividends and buybacks [11][13].

2022 — Pandemic normalization and emphasis on life-science growth engines

Post-COVID normalization occurred in some product lines while management restated medium-term targets and emphasized growth drivers in Healthcare, Life Science (EMD Millipore/Materials & Life Science), and Animal Health. Perception shifted from COVID-era volatility to a focus on structural growth areas. Investors began valuing Merck more for its life-science tools, specialty medicine pipeline, and animal-health franchises rather than one-off pandemic sales, viewing it as stable with selective growth optionality. Guidance language for 2022 described slight to solid organic growth and set payout ratio targets, with investor materials highlighting an aim for mid-single-digit organic growth corridors and focus on EBITDA pre margins [11].

2021 — Recovery from COVID-era dislocations and capital allocation focus

Fiscal-year 2021 results and 2021–2022 outlook reflected recovery from pandemic disruptions in some segments and re-emphasis on R&D and M&A to reshape the portfolio. Investors reacted to signs of recovery and to management's stated strategic priorities (innovation, selective acquisitions, shareholder returns), viewing the company as a large diversified life-science group undergoing structural repositioning. Some regarded it as a value compounder with cyclical elements tied to product launches and R&D success. 2021 and early-2022 investor materials and earnings releases framed net-sales recovery and set medium-term targets, with dividend increases resuming as part of returning earnings to shareholders [11][3].